Intellia Therapeutics, a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, will work alongside these experts to drive development of their ex vivo programmes in immuno-oncology and autoimmunity. The advisors hail from prestigious international institutions and collectively have both scientific and clinical expertise in cell therapies in these areas.
Professor Wood joins the company as one of Intellia’s advisors on ex vivo cell therapy in autoimmunity.